Belluscura plc announced that three additional U.S. patents have recently issued, increasing the number of issued and pending patent applications the Company owns or exclusively licenses to thirty. The technology covered by the patents, includes: Extracorporeal membrane oxygenation (ECMO) innovations for when people who are very ill with conditions of the heart and lungs, or who are waiting for or recovering from a heart transplant, require a portable artificial lung; Continuous Positive Airway Pressure (CPAP) innovations,a type of non-invasive ventilation (NIV) or breathing support, and; Consumer replaceable molecular sieve technology, used to remove Nitrogen from ordinary air to produce medical grade supplemental oxygen.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.652 GBX | -1.26% | -1.26% | -66.73% |
Apr. 02 | Belluscura sees financial hit from delay to closing TMT acquisition | AN |
Apr. 02 | AIM WINNERS & LOSERS: 88 Energy finds oil at Hickory-1; Redx to delist | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.73% | 15.9M | |
-3.38% | 185B | |
-4.15% | 107B | |
-5.03% | 67.55B | |
+8.89% | 54.6B | |
+16.24% | 47.42B | |
+3.86% | 42.24B | |
+8.33% | 28.24B | |
-0.37% | 26.42B | |
+12.40% | 25.66B |
- Stock Market
- Equities
- BELL Stock
- News Belluscura plc
- Belluscura plc Expands Its Oxygen Enrichment Patent Portfolio